title: Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
abstract: A series of 3-benzylidene-4-chromanones 1a-l were prepared and their cytotoxicity towards human Molt 4/C8 and CEM T-lymphocytes as well as murine L1210 lymphoid leukemia cells were compared to the previously generated biodata in these three assays for the isosteric 2-benzylidene-1-tetralones 2a-l. Over 40% of the compounds in series 1 were more potent than their counterparts in series 2, while equipotency was noted in one-third of the comparisons made. In general the IC(50) values of 1a-l towards the human T-lymphocytes were in the low micromolar range. Molecular modelling revealed differences in shapes of representative molecules in series 1 and 2 which may contribute to the variation in cytotoxic potencies. Most of the compounds in series 1 displayed greater potencies towards HSC-2, HSC-3, HSC-4 and HL-60 neoplasms than HGF, HPC, and HPLF normal cells and were well tolerated in mice.
authors: Institute of Pharmaceutical Chemistry, University of Pécs, P.O. Box 99, H-7602 Pécs, Hungary.
authors: Pal
authors: P
authors: Perjési
authors: Umashankar
authors: U
authors: Das
authors: Erik
authors: E
authors: De Clercq
authors: Jan
authors: J
authors: Balzarini
authors: Masame
authors: M
authors: Kawase
authors: Hiroshi
authors: H
authors: Sakagami
authors: James P
authors: JP
authors: Stables
authors: Tamas
authors: T
authors: Lorand
authors: Zsuzsanna
authors: Z
authors: Rozmer
authors: Jonathan R
authors: JR
authors: Dimmock
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D001578:Benzopyrans / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D007274:Injections, Intraperitoneal; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008958:Models, Molecular; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009474:Neurons / Q000187:drug effects; D013329:Structure-Activity Relationship; D015996:Survival Rate; D013601:T-Lymphocytes / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D001578:Benzopyrans
references: J Pharm Sci. 1993 Oct;82(10):988-91
references: 8254498
references: J Am Pharm Assoc Am Pharm Assoc. 1957 Mar;46(3):208-9
references: 13502156
references: Mini Rev Med Chem. 2007 Feb;7(2):131-9
references: 17305587
references: J Med Chem. 2002 Jul 4;45(14):3103-11
references: 12086496
references: Fundam Appl Toxicol. 1986 Feb;6(2):270-7
references: 3699317
references: J Med Chem. 1999 Apr 22;42(8):1358-66
references: 10212121
references: Eur J Med Chem. 2006 May;41(5):577-85
references: 16581158
references: Phytother Res. 2004 Mar;18(3):212-23
references: 15103668
references: Curr Med Chem. 2005;12(4):481-99
references: 15720256
references: J Enzyme Inhib Med Chem. 2003 Aug;18(4):313-24
references: 14567546
references: Curr Med Chem. 1999 Dec;6(12):1125-49
references: 10519918
references: J Med Chem. 2004 May 20;47(11):2877-86
references: 15139766
references: Anal Biochem. 1989 Mar;177(2):237-43
references: 2729541